Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-518-3 | CAS number: 38233-76-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
NOAEL Oral 28 days, male rats = 75 ppm in diet, equivalent to 7 mg/kg bw/day. LOAEL Oral 28 days, male rats = 150 ppm (13 mg/kg bw/day).
NOAEL Oral 28 days, female rats = 750 ppm in diet, equivalent to 61 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 15 Mar 1990 - 26 Apr 1990
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- The study was conducted in compliance with GLP; although no official test guideline was named in the study report, the methodology used was essentially consistant with official guidelines (such as OECD TG 407), and so the study is considered reliable with restrictions.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- Study methodology was essentially consistent with guideline, but no guideline was recorded in the Study Report.
- Deviations:
- not applicable
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: West- Germany
- Age at study initiation: ca. 4 weeks old
- Weight at study initiation: 131.2 g to 177.3 g (males) and 110.4 g to 144.3 g ( females)
- Housing: The rats were housed in groups of 5, males and females separated, in suspended, stainless steel cages, fitted with wire mesh floor and front.
For each sex the cages were randomly allocated to the various groups.
Each cage was provided with coloured card showing the animal identification numbers, the cage number, the group letter and the study number.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 9 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-24
- Humidity (%): 60-75
- Air changes (per hr): about 10
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From:15 Mar 1990 To: 12 Apr 1990 (main study) ; the rats of the recovery study were continued without treatment for a period of 14 days and sacrificed on 26 Apr 1990 - Route of administration:
- oral: feed
- Vehicle:
- not specified
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): Prepared twice during the course of the study.
- Mixing appropriate amounts with (Type of food): Basal diet.
- Storage temperature of food: -20°C - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Continuous (in diet).
- Remarks:
- Doses / Concentrations:
0, 150,300 or 1500 ppm
Basis:
nominal in diet - No. of animals per sex per dose:
- 5
5 additional animals per sex in the control and high dose level groups were used also. - Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale:The dose levels were selected by the sponsor
- Rationale for animal assignment (if not random): random - Positive control:
- No
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes (The general condition and behaviour of all animals were checked by cage- site observations)
- Time schedule: twice daily on working days and once a day on Saturdays, Sundays and public holidays (April 13 and 16, 1990)
BODY WEIGHT: Yes
- Time schedule for examinations: initially and at weekly intervals thereafter
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Food intake was measured per cage (5 rats/cage) per week by weighing the feeders, during the treatment period and the recovery period. The efficiency of food utilization was calculated and expressed as gram weight gain per gram food consumed
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Water consumption was measured per cage (5 rats/cage)
- Time schedule for examinations: Weekly on 4 consecutive days per week by weighing the water bottles
- This was done during the treatment period only
HAEMATOLOGY:
- Time schedule for collection of blood: on nominal day 28
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: No data
- How many animals: all animals
- Parameters checked : haemoglobin, packed cell volume, red blood cell count, red blood cell distribution width (RDW-SD), total white blood cell count, differential white blood cell count, prothrombin time (was also determined at the end of the recovery period - on nominal day 42), thrombocytes, mean plateled volume (MPV), platelet distribution width (PDW), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC),
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on day 26
- Animals fasted: No data
- How many animals: all rats
- Parameters checked: alkaline phosphatase activity, alanine aminotransferase activity, aspartate aminotransferase activity, gamma glutamyl transferase activitytotal protein, albumin, ratio albumin to globulin, urea, creatinine, bilirubin (total), sodium, potassium, calcium, chloride, inorganic phosphate, cholesterol, triglycerides. Plasma cholesterol and urea were also determined in the rats killed at the end of the recovery period (on nominal day 42)
URINALYSIS: Yes
- Time schedule for collection of urine: on nominal day 25-26
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked: volume, density, appearance, pH, occult blood, protein, glucose, ketone bodies, sediment: erythrocytes, leucocytes, epithelial cells, amorph material, crystals, casts, bacteria, sperm cells, worm eggs. all the urinary parameters, except for volume and density, were also examined in the recovery period, viz. on nominal day 40.
NEUROBEHAVIOURAL EXAMINATION: No data
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table below)
HISTOPATHOLOGY: Yes : liver, kidneys, heart, adrenals, and spleen were all examined microscopically. - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Prothrombin time was increased in males of the top- dose group at the end of the treatment period but not at the end of the recovery period. The other haematology parameters were unremarkable.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- A decreased cholesterol concentration and an increased urea concentration were observed in males of the top-dose group. At the end of recovery period , there were no diffrences other than an increased plasma urea concentration in females.
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The relative liver weight of top-dose females and the relative kidney weight of top- dose males were increased at the end of treatment.
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Refer below
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- Histopathology:
At the end of the administration period there were treatment-related renal changes in males, summarized as proximal tubular degeneration. The proximal tubular cells showed rounded intracytoplasmic hyaline inclusions of varying size, some resembling proteinaceous droplets, others resembling (deeply stained) acidophilic bodies. The renal tubules showed cellular degeneration and desquamation of epithelial cells. These changes occurred in males of all treatment groups, and were most severe at the highest dose level. At this level, kidneys also showed an increased number of basophilic tubules, possibly representing tubular regeneration. No tubular degeneration was observed in females. At the end of the 14-day recovery period all top-dose males still showed proximal tubular degeneration, though much less pronounced than at the end of the 28-day treatment period, and increased numbers of basophilic, most probably regenerating, tubules. - Dose descriptor:
- NOAEL
- Effect level:
- 750 ppm
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Equivalent to approximately 61 mg/kg bodyweight/day.
- Dose descriptor:
- LOAEL
- Effect level:
- 150 ppm
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: On the basis of observed nephrotoxicity. Equivalent to approximately 13 mg/kg bodyweight/day.
- Critical effects observed:
- not specified
- Conclusions:
- It can be concluded that the no-toxic-effect level for ED-TCD is 750 ppm (equivalent to about 61 mg/kg body weight/day) for female rats, and at least 75 ppm (equivalent to about 7 mg/kg body weight/day) but lower than 150 ppm (equivalent to about 13 mg/kg body weight/day) for male rats.
Reference
At the end of the administration period there were treatment-related renal changes in males, summarized as proximal tubular degeneration. The proximal tubular cells showed rounded intracytoplasmatic hyaline inclusions of varying size, some resembling proteinaceous droplets, others resembling (deeply stained) acidophilic bodies.
The renal tubules showed cellular degeneration and desquamation of epithelial cells.
These changes occurred in males of all treatments groups and were most severe at the highest dose level.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 7 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Two studies (TNO-CIVO, 1990, study ref V90.247, and TNO-CIVO, 1990, study ref V89.383) were conducted to assess the effects of repeat dose administration of ETD to rats by the oral (dietary) route. The methodology employed by each study was broadly consistent with the modern OECD test guideline 407. Both studies were conducted in compliance with GLP.
Dose groups of five rats per sex per dose were allowed free access to diet to which ETD had been added; dose levels were 150, 300, and 1500 ppm in study reference V90.247, and 75, 750, and 7500 ppm in study reference V89.383; a negative control level (provided with untreated diet) was included in each study. Rats were dosed for 28 days and observed for mortality or other signs of toxicity; animals were sacrificed at the end of the treatment period and a pathological examination performed. In each study, supplementary groups of 5 animals per sex were administered the highest dose level (1500 ppm or 7500 ppm) or untreated diet (negative controls) for 28 days, then observed for 14 days post-administration, to assess recovery following administration.
No animals died in either study at any dose level during the treatment or recovery periods. In each study, signs were seen of liver damage (increased prothrombin time seen in males at the 1500 ppm level, and in both sexes at the 7500 ppm level at the end of the treatment period, and increased liver weights in both sexes at 7500 ppm and at 1500 ppm), however evidence of recovery / reversal of these signs were seen following the 14 -day recovery period for the high-level animals in each study.
There were signs of renal damage in males at doses greater than 75 ppm in each study (signs included: increased kidney weight, the presence of occult blood and epithelial cells in urine, and histopathological renal lesions). As this effect was noted in males only, it was concluded that these effects may have been related to a specific toxic syndrome, alpha-2 microglobulin nephropathy, which may occur following exposure to a number of chemicals, principally hydrocarbons. This syndrome appears to be unique to the male rat (which is consistent with the fact that these renal signs were not observed in the female rats), and on this basis ETD is not considered to be of high concern for kidney damage in humans.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Selected study (CIVO, 1990) continues work conducted in an earlier study (CIVO, 1989). The later study included dose levels intermediate to those used in the 1989 study to better assess the effect threshold. Note that both studies are considered reliable as they were both conducted in compliance with GLP and used methodology broadly consistent with the modern OECD Test Guideline 407.
Justification for classification or non-classification
Apparent toxic effects were seen in the liver of animals treated at high doses, however these effects were seen to recover after the end of treatment. With reference to the CLP Regulation (Regulation (EC) 1272/2008), Annex I section 3.9.2.8.1 the effects seen in the liver in these studies are not considered to justify classification for Specific Target Organ Toxicity (STOT, Repeated dose). In addition, although effects were seen in the kidneys of male rats, as stated above because this effect is only seen in male rats, it is not considered to impact on human health, and so for the purposes of classification, kidneys are not considered to be a target organ.
As no data is available on target organ toxicity following repeated exposure by the inhaled or dermal routes, it cannot be stated conclusively that ETD will not cause repeated dose toxicity, and so STOT (repeated dose) is considered inconclusive for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.